The cluster is heavily weighted toward quant funds (Citadel, Millennium, D.E. Shaw) and passive mega-managers — a tactical bet on the near-term tovecimig catalyst rather than long-term conviction. Traders should monitor FDA feedback timing; a positive BLA acceptance could drive a re-rate, while a delay or negative feedback risks sharp reversal given no insider backing.
Executive Summary
A strong institutional cluster in CMPX shows 15 buyers adding $37.2M in positions (net +$9.2M) vs 5 sellers reducing by $21.5M, led by quant funds Citadel, Millennium, and D.E. Shaw doubling or adding aggressively. The accumulation follows Q2 2026 earnings where net loss improved modestly, and comes ahead of a potential BLA filing for tovecimig in biliary tract cancer — the primary catalyst for this pre-revenue biotech. No insider buying corroborates the move, weakening conviction slightly.
Key Financial Metrics
Institutional Positions
Net institutional flow: $9.2M
▲ Buyers (15)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Citadel | DOUBLED | +395% | $7.8M | $4.0M |
| Millennium | DOUBLED | +457% | $10.3M | $5.8M |
| D.E. Shaw | DOUBLED | +210% | $448.0K | $99.0K |
| Vanguard Portfolio Management | DOUBLED | +248.3% | $8.3M | $2.5M |
▼ Sellers (5)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Fidelity | TRIM | -32.7% | $9.5M | -$6.9M |
| UBS | TRIM | -70.2% | $12.7M | -$11.1M |
| BofA | TRIM | -34.5% | $4.6M | -$3.3M |
Key Facts
- 15 institutional buyers added net $9.2M in Q2 2026; 5 sellers reduced by $21.5M
- Citadel DOUBLED to $7.8M (Δ+$4.0M), Millennium DOUBLED to $10.3M (Δ+$5.8M), D.E. Shaw DOUBLED to $448K (Δ+$99K)
- Goldman Sachs ADDED 77% to $7.7M, Vanguard Portfolio Mgmt DOUBLED to $8.3M (Δ+$2.5M)
- Fidelity trimmed 32.7% (-$6.9M), UBS trimmed 70.2% (-$11.1M), BofA trimmed 34.5% (-$3.3M)
- Q2 2026 net loss $0.13/share vs $0.14 prior year; FDA feedback on tovecimig (BTC) pending with potential BLA filing in H2 2026
- No open-market insider buying confirmed in the window (institutions-only signal)
Financial Impact
15 buyers added net $9.2M to holdings of $37.2M; 5 sellers removed $21.5M. Quant funds alone injected ~$10M in new capital.
Risk Factors
- No insider buying corroboration — institutions only signal
- Pre-revenue biotech with binary regulatory catalyst; any setback could reverse gains sharply
- Passive mega-trims (Fidelity, UBS, BofA) total $21.5M in selling — supply overhang possible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CMPX-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $0.7697 | awaiting T+20 | — | — |
Sep 22, 2026 4w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | — |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | — |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | — |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | — |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | — |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | — |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | — |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | — |
May 5, 2026 24w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers